New clinical trial data in SMA were discussed during the latest edition of the World Muscle Society (WMS) congress from September 20-24, 2021.
Out of five pre-symptomatic infants under 6 weeks of age treated with Evrysdi (risdiplam) for at least one year in the RAINBOWFISH trial, all are able to swallow and feed exclusively orally, four are successful. stand up and walk independently.
Evaluated by the TOPAZ trial, apitegromab (or SRK-015) improves motor function in participants with type II or III SMA, aged 2 to 21 years, over one year.
Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders. Roche press release 2021-09-24.
Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress. Scholar Rock press release 2021-09-23.
